Home-Based Screening for Early Detection of Atrial Fibrillation in Primary Care Patients Aged 75 Years and Older

NCT02392754 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 856

Last updated 2020-01-27

No results posted yet for this study

Summary

Atrial fibrillation (AF) is a major treatable risk factor for stroke, but it may be hard to detect because it is frequently silent and intermittent. New ambulatory cardiac monitoring technologies have the potential to improve early detection of AF. This trial investigates AF screening in primary care patients using the ZIO XT Patch, a wearable adhesive patch monitor that provides continuous ECG recording for up to 14 days, in addition to the WatchBP home blood pressure monitor that has built-in AF screening capability.

Conditions

Interventions

DEVICE

Screening: Intervention - Atrial fibrillation screening (ZIO XT ECG monitor, Watch-BP)

The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.

Sponsors & Collaborators

  • Canadian Stroke Prevention Intervention Network

    collaborator OTHER
  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV
  • Heart and Stroke Foundation of Canada

    collaborator OTHER
  • Canadian Stroke Network

    collaborator OTHER
  • iRhythm Technologies, Inc.

    collaborator INDUSTRY
  • Microlife

    collaborator INDUSTRY
  • University of Leipzig

    collaborator OTHER
  • Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

    collaborator OTHER
  • Population Health Research Institute

    lead OTHER

Principal Investigators

  • David J. Gladstone, MD PhD FRCPC · Sunnybrook Research Institute, University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-01
Primary Completion
2019-10-21
Completion
2020-01-21

Countries

  • Canada
  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02392754 on ClinicalTrials.gov